Vimentin exhibits a complex pattern of developmentaland tissue-specific expression and is aberrantly expressed in most metastatic tumors. The human vimentin promoter contains multiple DNA elements, some of which enhance gene expression and one that inhibits. A silencer element (at À319) binds the repressor ZBP-89. Further upstream (at À757) is an element, which acts positively in the presence of the silencer element and, thus, is referred to as an antisilencer (ASE). Previously, we showed that Stat1a binds to this element upon induction by IFN-c. However, substantial binding and reporter gene activity was still present in nontreated cells. Here, we have found that Stat3 binds to the ASE element in vitro. Transfection experiments in COS-1 cells with various vimentin promoter--reporter constructs show that gene activity is dependent upon the cotransfection and activation of Stat3. Moreover, activated Stat3 can overcome ZBP-89 repression. Coimmunoprecipitation studies demonstrate that Stat3 and ZBP-89 can interact and confocal microscopy detects these factors to be colocalized in the nucleus. Moreover, a correlation exists between the presence of activated Stat3 and vimentin expression in MDA-MB-231 cells, which is lacking in MCF7 cells where vimentin is not expressed. In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation.
Introduction
IFs 1 (intermediate filaments) comprise a multigene family of nearly 50 different proteins, which exhibit tissue-and developmental-specific expression. Of the three cytoskeletal networks, actin, microtubules and the IFs, the IFPs (IF proteins) are probably the most complex and least understood. The family comprises both nuclear (lamins) and cytoskeletal proteins such as the keratins, vimentin, desmin, glial fibrillary acidic protein (GFAP), neurofilaments, internexin, nestin, and peripherin (Steinert and Liem, 1990; Parry and Steinert, 1992) . Within this multigene family, vimentin displays a complex pattern of gene expression. Vimentin is first expressed during development in mesodermal cells located between the primitive streak and the proximal endoderm (Duprey and Paulin, 1995) . Initially, it is widely expressed in the embryo, but is progressively restricted to fewer cell types during development. For example, in muscle, astrocytes, or neural differentiation, the vimentin gene is downregulated to make room for expression of the tissue-specific IFP genes desmin, GFAP, and neurofilaments, respectively. This restriction of gene expression is hypothesized to be due to negative regulation by the transcriptional repressor ZBP-89 (Passantino et al., 1998; Wieczorek et al., 2000; Zhang et al., 2003) . For the most part, vimentin expression coincides with cellular growth and is cell cycle regulated (Franke et al., 1979) . It is induced following serum withdrawal and refeeding and by a variety of growth factors and cytokines, such as FGF, TGF-b, PDGF, or IFN-g (Rittling and Baserga, 1987; Izmailova et al., 2000) . Recent interest in the epithelial-mesenchymal transition (EMT) suggests that vimentin is a diagnostic marker for the initial dissemination of cells from epithelial tissue to becoming migratory, metastatic tumor cells (Gilles and Thompson, 1996) . Therefore, an understanding of how the vimentin gene is regulated is important not only for understanding the IFP gene regulation, but also eucaryotic gene regulation in general and the relationship between gene expression and tumor progression.
To date, the following elements have been identified in the promoter region of the human vimentin gene: a TATA-box, several positive regulatory elements that include eight GC-boxes (Rittling and Baserga, 1987) , an NF-kB site , a PEA3 site (Chen et al., 1996) , D19 (Salvetti et al., 1993) , two tandem AP-1-binding sites (Rittling et al., 1989) , a bcatenin site (Gilles et al., 2003) , an antisilencer (ASE) element , and a proximal silencer element (Salvetti et al., 1993) . Previously, we have shown that the expression of the vimentin promoter is dependent on GC-box #1 located at position À64 from the start point for transcription. Mutation of GC-box #1 to a nonfunctional sequence results in little reporter gene expression, despite the addition of considerable upstream DNA . We have found that GCbox #1 binds either Sp1 or Sp3 , and the proximal silencer element (PS) binds ZBP-89 (Wieczorek et al., 2000) .
ZBP-89 (BERF-1, BFCOL1, ZNF148) is a zincfinger, Kruppel-like protein, which is thought to be ubiquitously expressed. ZBP-89 is a transcriptional repressor in the case of vimentin (Wieczorek et al., 2000) , epithelial neutrophil-activating peptide-78 (Keates et al., 2001) , gastrin (Merchant et al., 1996) , ornithine decarboxylase (Law et al., 1998b) , and bovine adrenodoxin (Cheng et al., 2000) genes. However, for other genes such as p21 (Hasegawa et al., 1999) , the Tcell a-and b receptor (Wang et al., 1993) , a lymphocytespecific protein-tyrosine kinase (lck) (Yamada et al., 2001) , type 1 collagen (Hasegawa et al., 1997) , and stromelysin (Ye et al., 1999) , it appears to activate gene expression. How ZBP-89 can function both as an activator and a repressor of gene expression is unknown. It has been proposed that for some genes, ZBP-89 and Sp1, can compete for binding to a GC-rich sequence (Law et al., 1998a) . However, in the case of vimentin, a separate PS element (at position À319 to À278) has been found, which does not directly bind Sp1 (Wieczorek et al., 2000) . Thus, in the vimentin gene, ZBP-89 and Sp1 (or Sp3) bind to separate DNA elements and interact by protein-protein interaction . We propose that this interaction accounts for the dependence of vimentin gene activity on a functional GC-box #1 and its associated factor (Wieczorek et al., 2000) .
Further upstream, we found an additional, positiveacting element. Originally, this element was found in the chicken vimentin gene where it was shown to be necessary and sufficient for FGF induction and contributed to the serum induction of vimentin expression (Carey and Zehner, 1995) . It was named an ASE because when fused to either the homologous chicken vimentin or the heterologous thymidine kinase basal promoter, it did not enhance gene expression unless the silencer element was also present (Stover and Zehner, 1992) . More recently, the corresponding ASE in the human vimentin gene has been located . Similarly, it seemed that this element also required a silencer element to be present in cis in order to exert a positive effect on gene expression. Therefore, it was important to identify the protein that binds to the ASE and determine if it interacts with the repressor ZBP-89 to overcome gene repression as predicted from earlier studies.
Here, we have established that the upstream ASE binds Stat3. Stats are a family of transcriptional activators, which play a central role in signaling pathways involving cytokines, growth factors, or peptide hormones (Ihle, 1996; Darnell, 1997; Horvath, 2000; Levy and Darnell, 2002) . Activated receptors are protein-tyrosine kinases of the JAK family, which phosphorylate Stats. Phosphorylated Stats form dimers via their SH2 domains and rapidly translocate to the nucleus where they bind regulatory DNA elements of target genes involved in cell proliferation, differentiation, apoptosis, and development. In retrospect, perhaps it is not surprising that the vimentin gene would be a possible target for Stat3 activation. However, these findings suggest a new mode of Stat3 activation whereby its interaction with ZBP-89 can overcome repression and restore gene expression.
Results

Electrophoretic mobility shift assays (EMSAs) suggest that the ASE binds Stat3
A transfac search program was used to search for known transcription factors that could bind to the ASE (Quandt et al., 1995) . As expected, part of the ASEbinding site (TTCCCCTAA) contains a potential Stat3-binding site (TTN 5 AA) (Bromberg, 2001) . No binding protein other than a Stat protein was suggested by this search. Previously, we showed that Stat1a binds to the ASE sequence, but only after interferon-g induction (Izmailova et al., 2000) . In this case, an additional, shifted band appeared on EMSAs. From the literature, it was apparent that Stat1 and Stat3 could bind DNA as either homodimers or heterodimers (Horvath, 2000) . Thus, EMSAs were used to determine if Stat3 could also bind to the ASE ( Figure 1 ).
As in most cancer cells, vimentin is highly expressed in MDA-MB-231 (MDA) cells. EMSAs with 32 P-labeled ASE (a 28-mer) and nuclear extracts (NE) prepared from MDA cells revealed several shifted bands ( Figure 1a , lane 2, bands 1-3). Binding specificity is demonstrated by competition with a 50-fold molar excess of unlabeled ASE DNA (lane 3) or a Stat3 element (lane 4), but no competition is detected with a 50-fold excess of nonspecific (NS) DNA (lane 5), that is, the multicloning site of pUC18. On the other hand, a 32 P-labeled Stat3 site (a 24-mer) generated two bands (labeled A and B) whose migration was similar to bands 1 and 2 for the ASE (Figure 1b, lane 2) . Neither band A nor B was obtained with a 32 P-labeled Stat3 mutant (S3m, lane 5) or bands 1-3 with a 32 P-labeled ASE mutant (ASMm, lane 3). The content of these shifted bands was further assessed by incubation with antibodies specific to Stat3 (anti-Stat3) in extracts from MDA cells treated with EGF for 1 h prior to harvesting. With these NEs, bands 1 and 3 disappear and band 2 remains as the only band-shift species detected with the ASE element (lane 2). Likewise, band B (lane 6) becomes the major band-shift species for the Stat3 element. In both cases, band 2 (lanes 3 and 4) and band B (lanes 7 and 8) can be ablated and/or supershifted with anti-Stat3 (SStat3). The same result is obtained whether NE and anti-Stat3 are preincubated prior to the addition of 32 P-labeled DNA (lanes 3 and 7) or NE and 32 P-labeled DNA are mixed prior to the addition of antiStat3 (lanes 4 and 8). More importantly, no ablation or supershifting of these bands could be detected with IgG (lanes 5 and 9, respectively). Here, it is apparent that the presence of band 2 and band B correlates with the enhanced content of activated Stat3 in MDA cells treated with EGF. Although the protein content of ASE bands 1 and 3 remains unknown, it is clear that this binding is minor in the presence of activated Stat3 where band 2 containing Stat3 is the only species detected. In addition, previous UV-crosslinking studies and Southwestern blots suggested that the ASE-binding protein was around 105 kDa in molecular weight, which approximates that of Stat3 .
Stat3 can enhance transcription of the vimentin gene
EMSAs confirm that activated Stat3 protein can bind to the ASE in vitro. However, could Stat3 enhance gene expression in transient transfection assays in vivo? In order to confirm that the ASE-binding protein is Stat3-dependent, COS-1 cells were cotransfected with pRcCMV-Stat3 and various vimentin promoter regions were fused to the reporter gene CAT (Figure 2 ). Construct p757 contains from nucleotide position À757 upstream of the transcriptional start site to þ 72 of the vimentin promoter, whereas construct p749 (À749 to þ 72) is deleted for the Stat3-binding site at position À757 to À749. A similar construct, p749-Ap1 (À749 to þ 72), contains mutant tandem Ap-1 elements. COS-1 cells were used due to their lack of activated Stat3 as verified by EMSAs (data not shown) and Western blots (Figure 2b) . At 24 h after transfection, cells were serum starved for 24 h and some treated with EGF (100 ng/ml) for 24 h prior to harvesting and assaying for CAT activity. Upon EGF treatment, Stat3-transfected cells exhibit a sixfold increase in reporter gene activity (Bromberg et al., 1999) . No increase in reporter gene activity was noted for COS-1 cells that were serum starved (DM), treated with EGF only (EGF), or transfected with Stat3 and not activated by EGF (Stat3 þ DM). Cotransfection of pRcCMA-Stat3 with construct p749, which lacks a Stat3-binding site, did yield a twofold increase in CAT activity upon treatment with EGF. However, mutation of the tandem Ap-1 sites in construct p749-Ap1 eliminated most of this induction. Previously, vimentin gene expression has been shown to be enhanced by these AP-1 sites (Rittling et al., 1989; Wu et al., 2003) . Recently, it has been reported by EMSAs and yeast two-hybrid analysis that Stat3 and cjun can interact in vitro. Moreover, this interaction was shown to enhance expression of a reporter gene (Zhang et al., 1999; Yoo et al., 2001) . Taken together, these results suggest that the twofold increase exhibited by the p749 construct is probably due to a Stat3/c-jun interaction, which is occurring independently of the Stat3-binding site.
Western blot analysis of COS-1 WCEs, using either anti-Stat3 or the phosphotyrosine-specific antibody (pY-705 Stat3), confirms the overexpression of Stat3 ( These results show that COS-1 cells can be manipulated to express higher levels of reporter gene activity from the p757 versus p749 construct upon cotransfection of Stat3 coupled with EGF activation. However, could a correlation between endogenously activated Stat3 and reporter gene activity be found in cell lines where the vimentin gene has been shown to be differentially expressed in relation to tumor promotion? To address this question, we examined the expression of such constructs in MDA versus MCF-7 breast cancer cell lines. We and others have shown that the MDA breast cancer cell line expresses high levels of vimentin as detected by Western and Northern blots and is metastatic (Sommers et al., 1989 (Sommers et al., , 1992 Stover and Zehner, 1992) . On the other hand, the MCF-7 breast cancer cell line does not express vimentin and is not metastatic (Sommers et al., 1989 (Sommers et al., , 1992 Stover and Zehner, 1992) . In the literature, it has been proposed that metastatic tumor cells like MDA contain constitutively activated Stat3, which could enhance the expression of Stat3-dependent genes thereby contributing to tumor progression (Bromberg et al., 1999; Bromberg, 2001; Garcia et al., 2001; Zajchowski et al., 2001; Levy and Darnell, 2002) . Nonmetastatic cell lines like MCF-7 should contain little activated Stat3 and thus gene activity should be low (Lim and Cao, 2001 ). However, to date no data have been shown to document such a proposed correlation between Stat3 and vimentin expression ( Figure 3 ). As expected, transient transfection of MDA cells with the p757 construct results in a high level of reporter gene activity, which was set as 100% ( Figure 4a ). However, the activity of the p749 construct lacking the ASE is reduced by 75% in this cell line. On the other hand, reporter gene activity for either construct in the MCF-7 cell line is low. An analysis of Stat3 content (Figure 4b 0 -end CAT constructs plus Stat3 expression plasmids. (a) COS-1 cells were transiently transfected with p757, p749, or p749-Ap1 constructs (1 mg) plus 1 mg of pRcCMV-Stat3 expression plasmids as described in 'Material and methods'. At 24 h after transfection, the medium was replaced with serum-free medium and the cells were harvested 24 h later (white box). EGF was added at a concentration of 100 ng/ml to cells in serum-free media for 24 h prior to harvesting (striped box). Cells were transfected with Stat3 appear that the protein content of band A might differ from band 1, since the later remains in M7 extracts and band A disappears. In any case, there is little doubt that the content of activated Stat3 differs between MDA and M7 extracts, which can contribute to the noted differences in vimentin gene expression.
Stat3 can interact with ZBP-89
Our previous studies indicated that the ASE-binding protein required a functional PS element and associated factor to exert its enhancing effect on gene expression (Stover and Zehner, 1992; We wondered if coimmunoprecipitation could be obtained with endogenous levels of Stat3 protein. Since COS-1 cells had little detectable endogenous Stat3, we turned to MDA cells for this analysis. We were forced to still transfect a Flag-ZBP-89 expression plasmid, because a reliable ZBP-89 antibody was not available. However, we were able to detect endogenous Stat3 coprecipitating with Flag-ZBP-89 in WCEs from MDA cells (Figure 5b) . Thus, we conclude that co-precipitation of ZBP-89 and Stat3 is not dependent on the overexpression of at least the Stat3 protein.
Finally, the colocalization of these proteins in vivo was examined by confocal microscopy ( Figure 5 ). COS-1 cells were cotransfected with pCMV-HA-ZBP-89 and pRcCMV-Stat3 plasmids as described above. Cells were incubated with polyclonal anti-HA (1 : 100) and monoclonal anti-Stat3 (1 : 200) for 1 h and then incubated with FITS-conjugated anti-rabbit and TRITC-conjugated anti-mouse antibody for 1 h. Images were viewed with a Zeiss confocal microscope. ZBP-89 is localized to the nucleus (panels a and d), whereas Stat3 can be found both in the cytoplasm and the nucleus (panels b and e) as expected (Meyer et al., 2002) . At best, only 10-30% of Stat3 is thought to translocate to the nucleus upon activation (Sehgal, 2000) . Upon overlay (panels c and f), the colocalization of ZBP-89 and Stat3 is clearly visible. Although not all ZBP-89 fluorescence is covered with Stat3, that is, some regions of sole green remain, a great deal of ZBP-89 is overlaid with Stat3. Since vimentin is a single copy gene, this suggests that there are probably other genes, which are regulated by the combination of the ZBP-89 repressor and Stat3 activator. In any case, this is physical evidence that these proteins are coexisting in the nucleus. 
Discussion
Although vimentin is expressed in many cell types during embryogenesis, its transcription is curtailed in certain tissues during terminal differentiation, suggesting a complex regulatory mechanism. It has been suggested that the PS element and its associated factor ZBP-89 play a role in repressing gene transcription during terminal differentiation (Passantino et al., 1998; Wieczorek et al., 2000; Zhang et al., 2003) . On the other hand, vimentin is aberrantly activated in many tumors despite their embryological origin, particularly as they become invasive and metastatic (Bowman et al., 2000) . As such, it has been cited as an important, diagnostic marker for changes in gene expression that occur during the EMT that predate tumor progression (Bussemakers et al., 1992; Gilles and Thompson, 1996; Zajchowski et al., 2001) . Thus, it is likely that vimentin's regulatory elements and cognate binding proteins interact with relevant global signals that are important for the timely control of cellular proliferation. An understanding of vimentin gene regulation may contribute to an understanding of tumor progression. Previously, it was suggested that the vimentin gene promoter contained an ASE, which unlike the usual enhancer element, required the presence of the silencer element, PS, in cis to activate fully transcription (Stover and Zehner, 1992; . Here, EMSAs (Figures 1 and 3) , transient transfection analyses (Figures 2 and 3) , and colocalization studies (Figures 4 and 5 ) support the conclusion that Stat3 is the ASE-binding protein. Coimmunoprecipitation studies show that Stat3 and ZBP-89 can interact. Although tyrosine-705 phosphorylation is not necessary for ZBP-89 to first recognize Stat3, it is important for subsequent effects on gene activity (Bromberg, 2001) . A correlation between the content of activated Stat3, reporter gene activity, and vimentin expression is apparent in MDA versus MCF-7 cells (Figure 3 ). More importantly, the expression of activated Stat3 can overcome ZBP-89 repression and supports our original definition of the ASE as an antisilencer.
To date, only a few silencer and ASE elements have been described for eucaryotic genes (Dobretsova and Wight, 1999; Malone et al., 2001) . Moreover, the details of how these elements might work to regulate gene expression are unknown, since in all other cases the required DNA sequence and binding protein have not yet been elucidated. To our knowledge, this is the first case where an ASE and associated factor has been identified. Moreover, due to the proven interaction between ZBP-89 and Stat3, we can suggest a mechanism of action. Previously, we have shown that the basic domain of ZBP-89 interacts with the glutamine-rich region of Sp1 when bound to DNA (Wieczorek et al., 2000; Zhang et al., 2003) . Since this is the same domain that interacts with TAF II 130 and the TFIID complex, we proposed that ZBP-89 blocks Sp1 from recruiting the transcription complex. In support of this theory, the overexpression of TAF II 130 circumvented repression and restored reporter gene activity . As a result of the additional interactions noted here, we propose that Stat3's binding to ZBP-89 might interrupt ZBP-89's ability to bind Sp1, thus freeing Sp1 to associate with the transcriptional complex and restore gene activity. Although these DNA-binding sites are not adjacent within vimentin's promoter region, these proteins may be juxtaposed within the context of chromatin (Wieczorek et al., 2000) . However, we cannot exclude the presence of additional bridging proteins between Stat3, ZBP-89, and/or Sp1. All of these proteins have been shown to form multiple interactions with additional regulatory molecules, such as Stat3 with c-jun or CBP (Zhang et al., 1999; Horvath, 2000) , or ZBP-89 with p300 or p53 Merchant, 2000, 2001) . In addition, Sp1 has been shown to interact with proteins of the transcriptional complex such as TAF II 55, TF II B, or YY1 (Seto et al., 1993; Emili et al., 1994) . Further experiments will be required to confirm this model, but it is consistent with the data acquired so far Wieczorek et al., 2000; Zhang et al., 2003) . The fact that the ASE-binding protein is Stat3 suggests how the vimentin gene might be activated in metastatic tumor cells despite their embryological origin. It has been suggested that Stat3 is an oncogene, which is ubiquitously expressed in many tissues, and activated by many ligands such as IL-6, PDGF, or EGF (Bromberg et al., 1999) . Likewise, the vimentin gene is induced by PDGF and EGF (Rittling and Baserga, 1987) . Many oncogenes, which simulate tyrosine kinases, can activate Stat3 (Schindler and Darnell, 1995) . For example, Stat3 activation is required for vsrc transformation, and vimentin is induced in v-srctransformed fibroblasts (Turkson et al., 1998) . Stat3 is constitutively active in many tumors such as lymphomas, leukemia, multiple myeloma, brain, breast, lung, head and neck, and prostate cancers (Bowman et al., 2000) , and the constitutively active form of Stat3 can mediate cellular transformation (Bromberg et al., 1999) . Likewise, where analysed, vimentin has been shown to be highly expressed in these same tumors (Bussemakers et al., 1992; Hsieh et al., 1995; Zajchowski et al., 2001) . Thus, a correlation between activated Stat3 and vimentin gene expression is indicated.
Moreover, it has been shown that the Stat3 protein plays an important role in the growth and survival of different breast cancers in culture and in vivo (Garcia et al., 2001; Zajchowski et al., 2001) . Maximal Stat3 activation is thought to result from the cooperation of different growth factor receptors, cytokine receptors, and nonreceptor tyrosine kinases. Thus, constitutive activation of Stat3 is more predominant in highly aggressive, metastatic breast cancers, and inhibiting Stat3 activation can block the malignant progression of breast tumors (Bowman et al., 2000; Garcia et al., 2001) . Cell lines derived from these metastatic tumors such as MDA cells overexpress vimentin. Here, we have shown that the p757 construct exhibits a sixfold increase in gene activity over p749 due to the inclusion of the ASEStat3-binding site. On the other hand, MCF-7 cells are not invasive, do not express vimentin, and upon transfection display little difference in CAT activity . Thus, we have shown that reporter gene activity coincides with the presence or absence of activated Stat3, substantiating a correlation between the expression of vimentin, activated Stat3, and tumor progression at least in these breast cancer cell lines.
It has been suggested that ZBP-89 is a negative regulator of cell growth as overexpression in two gastric tumor cell lines (GH4 and AGS) inhibited cellular proliferation as measured by [
3 H]thymidine incorporation into DNA and led to the cell cycle arrest of GH4 cells in G1 (Remington et al., 1997) . In this capacity, ZBP-89 could be thought of as a tumor suppressor. Although the status of Stat3 in these cells is unknown, it is interesting that a proven oncogene, Stat3, can interact with a suggested growth suppressor, ZBP-89, to restore gene expression. Recently, ZBP-89 has been shown to interact with and stabilize nuclear p53 . Thus, the interplay between Stat3 and ZBP-89 could be crucial for controlling cellular growth either by direct effects on gene expression such as for the vimentin gene or by interaction with other important cellular sensor proteins such as p53.
Currently, other investigators have shown that blocking constitutive Stat3 signaling can be used to inhibit cellular growth and promote apoptosis of Stat3-positive tumor cells in vitro and in vivo (Bowman et al., 2000) . Our studies would suggest that an alternative target might be to restore the activity of the repressor ZBP-89 at least for those genes subject to this mode of regulation. This will require a better understanding of how ZBP-89 functions as a repressor rather than an activator, and how its activity is controlled by signaling pathways, which might involve phosphorylation.
In summary, these results suggest that there is interplay between Stat3 and ZBP-89, which could contribute to the activation of vimentin gene expression during initial steps in tumor progression as what occurs in the EMT (Gilles and Thompson, 1996) . However, this may not be the only way to enhance vimentin gene expression, as current models of eucaryotic gene regulation suggest that various combinations of activators and/or repressors interact to modulate gene expression. For example, the stable transformation of MCF-7 cells with c-jun also leads to the activation of vimentin gene expression (Smith et al., 1999; Rinehart-Kim et al., 2000) . In this case, we have shown that c-jun functions as a coactivator with Sp1 to further enhance vimentin gene expression (Wu et al., 2003) . Recently, it has been proposed that a b-catenin/TCF site (at -468) can contribute to vimentin gene activation in some breast cancer cell lines, but not in MCF7 cells, and MDA cells were not investigated (Gilles et al., 2003) . Thus, multiple mechanisms must exist to enhance vimentin expression in various breast cancer cell lines. How important the interaction between Stat3 and ZBP-89 is to tumorgenesis in general will require the elucidation of other genes subject to this unique type of gene control. At the very least, these findings suggest a new mode for Stat3 regulation where Stat3 can activate gene expression by interacting with and thereby overcoming a repressor of gene transcription.
Material and methods
Plasmids
Various 5 0 -deletions of the human vimentin promoter fused to the CAT reporter gene were constructed as previously described . Construct p749-Ap1, which contained mutant Ap-1 sites (small letters), was made using the Quick-change, site-directed mutagenesis kit (Stratagene) and the wildtype p749 construct using the primer 5 0 -GGGCGCGG cacgtcaCCGCCGGcacctaaGCGACCCC-3 0 and its complement. Plasmid DNA content was confirmed by DNA sequencing.
Cell culture, transfection, and CAT assay MDA and COS-1 (monkey kidney) cells were maintained in MEM and D-MEM (DM), respectively, with glutamine, supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 mg/ml) (Gibco/BRL). Cells were transfected using either calcium phosphate or effectene as recommended by the manufacturer's protocol (Qiagen). Cells were harvested 48 h after the start of transfection, washed with PBS buffer, and lysates were prepared following freeze/ thawing three times (Nielsen et al., 1983) . To standardize between different transfections, pCMV-b-gal (1 mg) was cotransfected to serve as an internal control. CAT assays were performed using a liquid scintillation counting (LSC) assay adjusting the amount of cell extract used according to the b-gal activity of each transfection reaction (Seed and Sheen, 1988) . The values presented are the average of at least three separate transfections as noted.
Nuclear and whole-cell extracts
NEs were prepared from MDA cell cultures by the method of Dignam as previously described (Dignam et al., 1983) . WCEs were prepared by resuspending the cells in 1 Â lysis buffer (50 mM Tris (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, protease inhibitor cocktail at 10 ml/1 ml extract (Sigma), and phosphatase inhibitor cocktail II at 10 ml/1 ml extract (Sigma)). Protein concentration was determined by the BCA protein assay reagent (Pierce), and the aliquots were stored at À701C.
EMSA
EMSAs were carried out as previously described except that the reaction buffer contained 5 mM Tris-HCl (pH 7.0), 0.5 mM CaCl 2, 2.5 mM MgCl 2 , 1 mM dithiothreitol, 50 mg/ml BSA, 50 mM KCl, and 10% glycerol (Wu et al., 2003) . For competition assays, a 50-fold molar excess of unlabeled DNA fragment was incubated at room temperature for 30 min with the NE before adding the 32 P-labeled DNA. For supershift experiments, 2 mg antiStat3 antibody (Santa Cruz: sc-482X) was used. Oligonucleotides encompassing the human ASE or consensus Stat3-binding site or mutants thereof were synthesized as follows: wild-type ASE oligonucleotide, 5 0 -GGTCTAACGGTTTCCCTAAACCGCTAGG-3 0 ; mutant ASE olibonucleotide (ASEm), 5 0 -GGTCTAA CGGTGGACCTAAACCGCTAGG-3 0 ; wild-type Stat3-binding site, 5
0 -GATCCTTCTGGGAATTCCTAGA TC-3 0 ; mutant Stat3-binding site (S3m), 5 0 -GATCC TTCTGGGCCGTCCTAGATC-3 0 , plus their respective compliment strands. Underlining indicates the nucleotides that were changed in the mutant sequence.
Western blots
WCEs were separated on a 10% SDS-PAGE and transferred to a nitrocellulose membrane by electrophoresis at 150 V for 45 min at 41C. The membrane was blocked with 5% Blotto A (Santa Cruz) in TBS containing 0.05% Tween 20 (TBST) for 1 h at room temperature, and then incubated with the primary antiStat3 (Santa Cruz: sc-482) or anti-phospho-Stat3 (Tyr 705) (sc-8059) at a 1 : 1000 dilution as above for 1 h at room temperature. The membrane was washed three times in TBST and incubated with horseradish peroxidase-conjugated secondary antibody and treated as above for the primary antibody. The specific antigenantibody interactions were detected using an ECL kit (Amersham/Pharmacia).
Immunoprecipitation pCMV-Flag-ZBP-89 or pRcCMV-Stat3 plasmids were transiently transfected into COS-1 or MDA cells with effectene transfection reagent (Qiagen) according to the manufacturer's recommended protocol. At 48 h after transfection, cells were washed with ice-cold PBS and WCEs were prepared as described earlier (Dignam et al., 1983) . WCE (500 mg) was mixed with 5 mg of antibody and 50 ml of protein A/G PLUSAgarose (Santa Cruz) and incubated with rocking overnight at 41C. The antigen-antibody complexes were washed three times with 1 Â lysis buffer as described above. After washing, the beads were resuspended in 1 Â SDS-PAGE loading buffer and heated prior to loading on a gel. Proteins were separated on a 10% SDS-PAGE and then transferred to nitrocellulose membrane for Western blotting. Anti-Stat3 (C-20, Santa Cruz) or anti-Flag (M2, Sigma-Aldrich) was used for immunoprecipitation.
Immunofluorescence COS-1 cells (2 Â 10 4 ) were plated in 24-well plates with coverslips. Cells were cotransfected with pCMV-HA-ZBP-89 and pRcCMV-Stat3 plasmids. 48 h after transfection, cells were fixed with cold methanol at À201C for 5 min, washed with PBS, and blocked with 5% BSA, 0.1% Triton X-100 in PBS for 1 h. Cells were incubated with polyclonal anti-HA (Y-11) and monoclonal antiStat3 (Transduction Laboratories) in a dilution of 1 : 100 and 1 : 200, respectively, for 1 h. Next, the cells were incubated with FITC-conjugated anti-rabbit and TRITC-conjugated anti-mouse antibody (1 : 200, Jackson ImmunoResearch Laboratories) for 1 h. Images were viewed with a Zeiss confocal microscope.
